Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 809 across all filing types
Latest filing 2026-03-20 Earnings Release
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
Risultati Diasorin FY 2025
Earnings Release Classification · 95% confidence The document is a press release from Diasorin S.p.A. titled 'Risultati Diasorin FY 2025' (Diasorin FY 2025 Results). It provides a detailed summary of financial performance, including revenue, EBITDA, and net income, as well as guidance for 2026 and dividend proposals. While it mentions that the Board of Directors approved the consolidated financial statements, the document itself is a 'Comunicato Stampa' (Press Release) summarizing these results rather than the full statutory Annual Report (10-K) or a standalone audit report. According to the 'Menu vs Meal' rule, this is the initial announcement of financial results, which falls under the Earnings Release category. FY 2025
2026-03-20 Italian
Report on the treasury shares buy-back plan of Diasorin S.p.A. – Period 9/3/2026 – 13/3/2026
Transaction in Own Shares Classification · 100% confidence The document is titled 'Report on the treasury shares buy-back plan of Diasorin S.p.A.' and details the number of treasury shares purchased, the average price, and total consideration over a specific period (March 9, 2026 to March 13, 2026). It includes detailed daily purchase data and references a buy-back plan authorized by the shareholders' meeting. The content is focused on the company's repurchase of its own shares, which aligns with the category of Transaction in Own Shares. The document is substantive and not merely an announcement of a report or a certification. Therefore, it fits the 'Transaction in Own Shares' category (POS).
2026-03-13 Italian
Informativa sul programma di acquisto di azioni proprie di Diasorin S.p.A. - Periodo 09/3/2026 – 13/3/2026
Regulatory Filings
2026-03-13 Italian
Report on the treasury shares buy-back plan of Diasorin S.p.A. – Period 02/03/2026 – 06/03/2026
Transaction in Own Shares Classification · 95% confidence The document is titled 'Report on the treasury shares buy-back plan of Diasorin S.p.A.' and provides detailed information about the number of treasury shares purchased, the average price, and total consideration over a specific period (March 2, 2026 to March 6, 2026). It includes a detailed table of daily purchases and transaction details, indicating it is a report on share repurchase activity. The document is about the company's own shares buy-back plan and the actual transactions executed. This matches the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares. The document is substantive and not merely an announcement or a brief summary, and it does not fit other categories such as capital updates or regulatory filings. Therefore, the correct classification is POS with high confidence.
2026-03-06 Italian
Informativa sul programma di acquisto di azioni proprie di Diasorin S.p.A. - Periodo 02/03/2026 – 06/03/2026
Transaction in Own Shares Classification · 100% confidence The document is a detailed weekly disclosure about the company's own share buyback program, including the number of shares purchased, average prices, and total consideration over a specific period (02/03/2026 – 06/03/2026). It references compliance with EU Regulation 1052/2016 and provides granular transaction data. The content focuses on the company's transactions in its own shares rather than financial results, management changes, or other report types. The document length is substantial (15,000 characters) and contains detailed transactional data, not just an announcement of a report. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which reports on share repurchase activities.
2026-03-06 Italian
Report on the treasury shares buy-back plan of Diasorin S.p.A. – Period 23/2/2026 – 27/2/2026
Transaction in Own Shares Classification · 100% confidence The document is a report detailing the company's treasury share buy-back activities over a specific period (February 23-27, 2026). It includes aggregate data and a detailed list of individual transactions, which is a standard requirement for share repurchase programs. According to the filing definitions, 'Transaction in Own Shares' (POS) is the correct category for reports of a company buying back its own shares.
2026-02-27 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.